<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457336</url>
  </required_header>
  <id_info>
    <org_study_id>SPR001-203</org_study_id>
    <secondary_id>CAHmelia 203</secondary_id>
    <nct_id>NCT04457336</nct_id>
  </id_info>
  <brief_title>A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects With Classic Congenital Adrenal Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spruce Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spruce Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigation of the efficacy and safety of up to 52 weeks of treatment with Tildacerfont
      in subjects with classic CAH who have elevated biomarkers at baseline on their current GC
      regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study that will test the efficacy and safety of Tildacerfont. The first 12-weeks
      will be a double-blind, placebo controlled, dose ranging study. The following 40-weeks will
      assess the long term safety of Tildacerfont.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in a 1:1 manner to one of three doses of Tildacerfont or Placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in androstenedione [time frame: up to 3 months]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage change from baseline of androstenedione at Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events (safety analysis) [Time Frame: up to 12 months]</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number and percentage of participants with treatment-emergent adverse events and serious adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in adrenal hormones [time frame: up to 12 months]</measure>
    <time_frame>52 weeks</time_frame>
    <description>Percentage change from baseline of androstenedione, adrenocorticotropic hormone, and 17-hydroxyprogesterone</description>
  </other_outcome>
  <other_outcome>
    <measure>Normalization of androstenedione [time frame: up to 12 months]</measure>
    <time_frame>52 weeks</time_frame>
    <description>Number and percentage of participants on treatment achieving androstenedione levels below the upper limit of normal, matched for age and sex</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Tildacerfont Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tildacerfont Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tildacerfont Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tildacerfont administered daily via oral tablet for 12 weeks at dose level 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered daily via oral tablet for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tildacerfont/Placebo</intervention_name>
    <description>Tablet, administered daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tildacerfont Group 1</arm_group_label>
    <arm_group_label>Tildacerfont Group 2</arm_group_label>
    <arm_group_label>Tildacerfont Group 3</arm_group_label>
    <other_name>SPR001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 18 to 55 years old, inclusive

          -  Has a documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency
             based on genetic mutation in CYP21A2 and/or elevated 17-OHP

          -  Has been on a stable dose of GC replacement ≥15 mg/day and ≤50 mg/day in HC
             equivalents

          -  For subjects with the salt-wasting form of CAH, subject has been on a stable dose of
             mineralocorticoid replacement for ≥3 months before screening

        Exclusion Criteria:

          -  Has a known or suspected diagnosis of any other known form of classic CAH (not due to
             21 hydroxylase deficiency)

          -  Has a history that includes bilateral adrenalectomy or hypopituitarism

          -  Has a history of allergy or hypersensitivity to Tildacerfont or any other CRF1
             receptor antagonist

          -  Current treatment with dexamethasone as GC therapy for CAH

          -  Shows clinical signs or symptoms of adrenal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakie Sarafoglou, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Pediatrics, Divisions of Endocrinology and Genetics &amp; Metabolism, Univ. of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David M Moriarty, PhD</last_name>
    <phone>6508629761</phone>
    <email>dmoriarty@sprucebiosciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Rems</last_name>
    <phone>9257195041</phone>
    <email>nrems@sprucebiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spruce Clinical Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clarahealth.com/studies/cahmelia</url>
    <description>CAHmelia screening website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAH</keyword>
  <keyword>Adrenal Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

